Combination Therapy in RCC: Expert Guidance to Individualize Treatment and Improve Outcomes
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with RCC.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with RCC.
Upon completion of this activity, participants should be able to:
- Identify patients most likely to benefit from immune checkpoint inhibitor–based combination therapy based on risk and biomarker assessment, along with patient medical and treatment history
- Select optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
- Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
- Plan therapeutic strategies that optimize the sequence of therapies to provide the best possible outcome to patients with RCC
- Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC
Eric Jonasch, MD
Associate Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Neeraj Agarwal, MD
Associate Professor of Medicine
Division of Medical Oncology
Director, GU Medical Oncology
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah
Elizabeth Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Neeraj Agrawal, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Immunomedics, Janssen, Lilly, MEI Pharma, Merck, and ODM type.
Eric Jonasch, MD, has disclosed that he has received funds for research from Aravive, Merck, and Novartis and consulting fees from Aravive, Aveo, Eisai, Exelixis, Merck, NiKang, Novartis, and Pfizer.
Elizabeth Plimack, MD, MS, has disclosed that she received funds for research support from Aveo, AstraZeneca, Bristol Myers Squibb, Genentech, and Merck and consulting fees from Aveo, AstraZeneca, Bristol Myers Squibb, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, and Seattle Genetics.
The activity planning staff listed below discloses no relevant financial relationships:
CCO: Kristen Rosenthal, PhD; Shara Pantry, PhD; Timothy A. Quill; PhD, Jason J. Everly, PharmD; June Wasserstrom; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The NCCN clinical staff listed below discloses no relevant financial relationships:
Angela Motter, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-037-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 1.50 AAPA Category 1 CME credit
- 1.50 ACPE contact hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 Participation